Plasma anhydro‐<scp>d</scp>‐glucitol (1,5‐AG) as an indicator of hyperglycaemic excursions in pregnant women with diabetes

Dworacka, Marzena; Wender-Ożegowska, Ewa; Winiarska, Hanna; Borowska, Magdalena; Zawiejska, Agnieszka; Pietryga, Marek; Brązert, Jacek; Szczawińska, K; Bobkiewicz-Kozlowska, T.

doi:10.1111/j.1464-5491.2005.01752.x

Cited by 22 publications

(18 citation statements)

References 24 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of 1,5-AG is stable among normal subjects but significantly decreases among diabetic patients. This compound has been proposed and validated early in Japan [2][3][4][5][6][7] and recently in the US [8][9][10][11][12] as a marker for short-term glycemic control. The assay of 1,5-AG (GlycoMark TM ) was granted marketing clearance by the US Food and Drug Administration (FDA) in 2003, with the enzymatic method operated on Hitachi 917 chemistry analyzer [13].…”

Section: Introductionmentioning

confidence: 99%

Determination of glycemic monitoring marker 1,5-anhydroglucitol in plasma by liquid chromatography-electrospray tandem mass spectrometry

Li¹,

Heng²,

Wang³

et al. 2008

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Determination of glycemic monitoring marker 1,5-anhydroglucitol in plasma by liquid chromatography-electrospray tandem mass spectrometry

Li¹,

Heng²,

Wang³

et al. 2008

Journal of Chromatography B

View full text Add to dashboard Cite

“…1,5-AG is accepted by the U.S. Food and Drug Administration as a tool of monitoring glycemic control of diabetic patients. There were already some groups of patients described for whom 1,5-AG should not be recommended as a diabetes control measure owing to a low renal threshold for glucose, such as pregnant women and patients with end-stage renal disease (7,8), although some promising attempts of its use in gestational diabetes were described (15). In addition, there were some efforts to use 1,5-AG as a screening tool in diabetes (16,17).…”

mentioning

confidence: 99%

Clinical Application of 1,5-Anhydroglucitol Measurements in Patients with Hepatocyte Nuclear Factor-1α Maturity-Onset Diabetes of the Young

et al. 2008

View full text Add to dashboard Cite

OBJECTIVE -1,5-anhydroglucitol (1,5-AG) is a short-term marker of metabolic control in diabetes. Its renal loss is stimulated in hyperglycemic conditions by glycosuria, which results in a lowered plasma concentration. As a low renal threshold for glucose has been described in hepatocyte nuclear factor-1␣ (HNF-1␣) maturity-onset diabetes of the young (MODY), the 1,5-AG level may be altered in these patients. The purpose of this study was to assess the 1,5-AG levels in patients with HNF-1␣ MODY and in type 2 diabetic subjects with a similar degree of metabolic control. In addition, we aimed to evaluate this particle as a biomarker for HNF-1␣ MODY.RESEARCH DESIGN AND METHODS -We included 33 diabetic patients from the Polish Nationwide Registry of MODY. In addition, we examined 43 type 2 diabetic patients and 47 nondiabetic control subjects. The 1,5-AG concentration was measured with an enzymatic assay (GlycoMark). Receiver operating characteristic (ROC) curve analysis was used to evaluate 1,5-AG as a screening marker for HNF-1␣ MODY.RESULTS -The mean 1,5-AG plasma concentration in diabetic HNF-1␣ mutation carriers was 5.9 g/ml, and it was lower than that in type 2 diabetic patients (11.0 g/ml, P ϭ 0.003) and in nondiabetic control subjects (23.9 g/ml, P Ͻ 0.00005). The ROC curve analysis revealed 85.7% sensitivity and 80.0% specificity of 1,5-AG in screening for HNF-1␣ MODY at the criterion of Ͻ6.5 g/ml in patients with an A1C level between 6.5 and 9.0%.CONCLUSIONS -1,5-AG may be a useful biomarker for differential diagnosis of patients with HNF-1␣ MODY with a specific range of A1C, although this requires further investigation. However, the clinical use of this particle in diabetic HNF-1␣ mutation carriers for metabolic control has substantial limitations.

show abstract

“…70,71 Levels of 1,5-AG decrease during normal gestation in the presence of detectable glycosuria, secondary to changes in the renal threshold to glucose during pregnancy, 61 confirming that 1,5-AG levels in pregnant women are low independently of serum glucose. SMBG continues to be the cornerstone of hyperglycemia management during pregnancy, and it should be considered an empowering tool for patients and their doctors to decrease fetal and maternal complications.…”

mentioning

confidence: 88%

The Challenge of the Use of Glycemic Biomarkers in Diabetes: Reflecting on Hemoglobin A1C, 1,5-Anhydroglucitol, and the Glycated Proteins Fructosamine and Glycated Albumin

Wright¹,

Hirsch²

2012

Diabetes Spectrum

View full text Add to dashboard Cite

F r o m r e s e a r c h t o P r a c t i c e / G ly c e m i c m a r k e r s : a r e v i e w o F t h e t o o l s w e a l l l o v e , P e r h a P s t o o D e a r ly ? In BriefThis article reviews the advantages and limitations of the current glycemic biomarkers, including A1C, 1,5-anhydroglucitol, and the glycated proteins fructosamine and glycated albumin. It provides patient encounter case studies and related discussion to guide health care professionals on the appropriate use of the various glycemic biomarkers in clinical practice.

show abstract

Plasma anhydro‐d‐glucitol (1,5‐AG) as an indicator of hyperglycaemic excursions in pregnant women with diabetes

Abstract: The plasma 1,5-AG level may be a useful marker of daily glucose excursion in pregnant women with diabetes, as an adjunct to HbA(1c) monitoring.

Cited by 22 publications

References 24 publications

Determination of glycemic monitoring marker 1,5-anhydroglucitol in plasma by liquid chromatography-electrospray tandem mass spectrometry

Determination of glycemic monitoring marker 1,5-anhydroglucitol in plasma by liquid chromatography-electrospray tandem mass spectrometry

Clinical Application of 1,5-Anhydroglucitol Measurements in Patients with Hepatocyte Nuclear Factor-1α Maturity-Onset Diabetes of the Young

The Challenge of the Use of Glycemic Biomarkers in Diabetes: Reflecting on Hemoglobin A1C, 1,5-Anhydroglucitol, and the Glycated Proteins Fructosamine and Glycated Albumin

Contact Info

Product

Resources

About